Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This study aimed to compare the prognosis and characteristics of patients with advanced hepatocellular carcinoma treated with first-line atezolizumab plus bevacizumab (AB) combination therapy and hepatic artery infusion chemotherapy (HAIC). We retrospectively assessed 193 and 114 patients treated with HAIC and AB combination therapy, respectively, between January 2018 and May 2023. The progression-free survival (PFS) of patients treated with AB combination therapy was significantly superior to that of patients treated with HAIC ( < 0.05), but there was no significant difference in overall survival (OS). After propensity score matching, our data revealed no significant differences in OS and PFS between patients who received AB combination therapy and those who received HAIC therapy ( = 0.5617 and 0.3522, respectively). In conclusion, our propensity score study reveals no significant differences in OS and PFS between patients treated with AB combination therapy and those treated with HAIC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487133 | PMC |
| http://dx.doi.org/10.3390/cancers15174233 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
From clinical trials to daily practice: how to adequately administer sulbactam-durlobactam? alone or combined with imipenem?
Curr Opin Infect Dis
September 2025
Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna.
Purpose Of Review: Sulbactam-durlobactam (SUL-DUR) is a novel β-lactam/β-lactamase inhibitor combination recently approved for carbapenem-resistant Acinetobacter baumannii (CRAB) infections. This review summarizes current knowledge on the optimal use of SUL-DUR, whether administered alone or in combination with carbapenems, particularly imipenem.
Recent Findings: Data from registrational trial demonstrate that SUL-DUR is an effective and well tolerated treatment option for CRAB severe infections.
Self-Bondable and Strain-Durable Electroceuticals Using Self-Healing and Stretchable Conducting Nanocomposite Trilayer for Effective Vagus Nerve Stimulation.
ACS Nano
September 2025
Department of Electrical and Computer Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Vagus nerve stimulation (VNS) is a promising therapy for neurological and inflammatory disorders across multiple organ systems. However, conventional rigid interfaces fail to accommodate dynamic mechanical environments, leading to mechanical mismatches, tissue irritation, and unstable long-term interfaces. Although soft neural interfaces address these limitations, maintaining mechanical durability and stable electrical performance remains challenging.
View Article and Find Full Text PDFCombinatorial targeting of PI3K/AKT pathway with BKM120 increases cisplatin sensitivity and apoptotic response in A549 lung cancer cells.
Cell Mol Biol (Noisy-le-grand)
September 2025
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Despite significant advancements in the treatment of non-small cell lung cancer (NSCLC) using conventional therapeutic methods, drug resistance remains a major factor contributing to disease recurrence. In this study, we aimed to explore the potential benefits of combining PI3K inhibition with Cisplatin in the context of NSCLC-derived A549 cells. Human non-small cell lung cancer A549 cells were cultured and treated with BKM120, cisplatin, or their combination.
View Article and Find Full Text PDFAnti-inflammatory and immunomodulatory effect of purslane and turmeric in rheumatoid arthritis rat models.
Cell Mol Biol (Noisy-le-grand)
September 2025
Department of Chemistry, Faculty of Science and Health, Koya University, Koya, KOY45, Kurdistan Region, Iraq.
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by joint inflammation. Given the side effects of conventional treatments, this study focuses on the anti-inflammatory effects of purslane (Portulaca oleracea) and turmeric (Curcuma longa). The research is driven by the growing demand for plant based-treatment for safer therapeutic options for RA management.
View Article and Find Full Text PDFAn Indirect Treatment Comparison of Avalglucosidase Alfa versus Cipaglucosidase Alfa Plus Miglustat in Patients with Late-Onset Pompe Disease.
Adv Ther
September 2025
Sanofi, Gentilly, France.
Introduction: No head-to-head studies comparing the efficacy of avalglucosidase alfa (AVA) with cipaglucosidase alfa + miglustat (Cipa+mig) have been conducted in patients with late-onset Pompe disease (LOPD). Two indirect treatment comparisons (ITCs) were conducted to estimate the effects of AVA versus Cipa+mig.
Methods: ITCs were conducted using simulated treatment comparisons (STCs), adjusting for differences in prognostic factors and treatment effect modifiers.